Geron dramatic 2H 2012 ahead

Geron Corporation (GERN) appears to have a dramatic 2H 2012 ahead of it with its telomerase inhibitor, Imetelstat, having topline data being released for phase II trials in breast cancer and for multiple myeloma. Telomerase appears to be a good target for attacking cancer because most cancers have high levels of telomerase activity according to the company s website. Adding to the therapy's potential value in fighting cancer in an adjuvant setting with paclitaxel and/or bevacizumab for breast cancer and with/without lenalidomide for multiple myeloma, the drug is also in phase II trials for non-small cell lung cancer and Essential Thrombocythemia (ET) or Polycythemia Vera (PV). However, promising data in preclincals indicating efficacy in inhibiting cancer stem cells (CSC) growth in a broad range of tumors could turn into a huge catalyst in upcoming years. CSC's are thought to be responsible for the recurrent nature and metastasis of many cancers, and solid efficacy in advanced trials could prove to be a significant event as this indication is further investigated.
As important as Imetelstat can be for its currently targeted indications, the greater upside in the event of success in both efficacy and safety will be realized if the drug validates itself for any one of these indications. Success in one indication can mean real or perceived success in the many other cancers with elevated telomerase activity. The upside here can be significant, while the corresponding downside is also present as failure in a phase II trial could also mean real or perceived failure of the drug's efficacy/safety in most/all other indications.
Geron closed up 1 penny at $1.47 on 581,575 shares. The three month avg. volume is 651,383 shares. If Geron's  four Phase 2 trials results are good we should hit $5.00 if not 50 cents is possible.

ACTC under 7 cents not good. No news, we will go lower.

AAPL closed up at $587.41 it's the only stock I have in the green.

Good luck in this rigged casino,